Janicki, AJ.

We first want to thank Peters and colleagues for their interest in our work. They bring up two notable points in discussing our study.

We utilized three-lead Nasiff CardioHolter monitors to assess physiologic parameters. The raw data was downloaded directly from Holter monitors using Nasiff software and then reviewed by study authors to ensure quality data was obtained. While there was some motion artifact throughout the shift, the majority of the data was reliable with discernible QRS complexes in one of the three leads. We did not quantify the amount of artifact in each reading. This data was then analyzed using the provided software. When designing the study, we felt that a three-lead Holter, although less convenient and comfortable, would afford us additional data over pulse rate sensors. We do acknowledge as a limitation that we cannot account for all data obscured by artifact as we cannot control how the software decides to analyze and provide specific summary measures.

Finsterer, J.

With interest we read the review article by Valiuddin et al. about the neurological implications of coronavirus disease 2019 (COVID-19) (neuro-COVID).1 The authors listed ischemic stroke, transverse myelitis, seizures, acute hemorrhaghic necrotising encephalopathy (AHNE), acute disseminated encephalo-myelitis (ADEM), posterior reversible encephalopathy syndrome (PRES), myasthenia, and sinus venous thrombosis as central nervous system (CNS) manifestations, and hyposmia/hypogeusia, Guillain-Barré syndrome, facial palsy, ophthalmoparesis, and neuropathy, as peripheral nervous system (PNS) manifestations of COVID-19.1 We have the following comments and concerns.